4-76180995-G-C
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PM2BP4_StrongBP6BS1
The NM_005506.4(SCARB2):āc.382C>Gā(p.Pro128Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000189 in 1,613,222 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005506.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCARB2 | NM_005506.4 | c.382C>G | p.Pro128Ala | missense_variant | 3/12 | ENST00000264896.8 | NP_005497.1 | |
SCARB2 | XM_047416429.1 | c.-93C>G | 5_prime_UTR_variant | 3/12 | XP_047272385.1 | |||
SCARB2 | XM_047416430.1 | c.-93C>G | 5_prime_UTR_variant | 3/12 | XP_047272386.1 | |||
SCARB2 | NM_001204255.2 | c.276-5085C>G | intron_variant | NP_001191184.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCARB2 | ENST00000264896.8 | c.382C>G | p.Pro128Ala | missense_variant | 3/12 | 1 | NM_005506.4 | ENSP00000264896.2 |
Frequencies
GnomAD3 genomes AF: 0.00103 AC: 156AN: 152010Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000271 AC: 68AN: 250876Hom.: 0 AF XY: 0.000170 AC XY: 23AN XY: 135590
GnomAD4 exome AF: 0.000102 AC: 149AN: 1461094Hom.: 0 Cov.: 30 AF XY: 0.0000922 AC XY: 67AN XY: 726812
GnomAD4 genome AF: 0.00103 AC: 156AN: 152128Hom.: 0 Cov.: 32 AF XY: 0.000888 AC XY: 66AN XY: 74364
ClinVar
Submissions by phenotype
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 02, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Mar 04, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 21, 2015 | - - |
Action myoclonus-renal failure syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Mar 30, 2021 | SCARB2 NM_005506.3 exon 3 p.Pro128Ala (c.382C>G): This variant has not been reported in the literature but is present in 0.3% (82/24022) of African alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/rs143558324). This variant is present in ClinVar (Variation ID:196412). Evolutionary conservation and computational predictive tools for this variant are unclear. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. - |
Focal segmental glomerulosclerosis Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Oct 01, 2018 | - - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Nov 30, 2016 | - - |
SCARB2-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 08, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 26, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Progressive myoclonic epilepsy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at